whether
influenza
vaccin
influenc
sever
ill
case
clinic
failur
solid
organ
transplant
sot
recipi
receiv
influenza
vaccin
extens
studi
goal
evalu
frequenc
influenza
vaccin
among
sot
recipi
influenza
diseas
impact
ill
sever
season
adult
sot
recipi
confirm
influenza
infect
includ
decemb
april
followup
data
record
antibodi
titr
determin
use
microneutr
assay
sixtyfour
sot
recipi
includ
studi
ten
sever
diseas
requir
admiss
intens
care
unit
four
die
receiv
season
influenza
vaccin
receiv
pandem
vaccin
none
detect
antibodi
influenza
time
diagnosi
influenza
infect
twentythre
patient
receiv
vaccin
requir
hospit
admiss
present
less
dyspnoea
versu
p
pneumonia
versu
p
rel
risk
ci
unvaccin
patient
rel
risk
reduct
respect
although
influenza
vaccin
confer
protect
sot
recipi
develop
influenza
pneumonia
rate
clinic
failur
still
high
new
strategi
improv
influenza
immun
need
group
patient
respiratori
infect
especi
influenza
infect
major
caus
morbid
mortal
solid
organ
transplant
sot
recipi
influenza
infect
caus
complic
includ
primari
secondari
viral
pneumonia
prolong
period
viral
shed
sinc
last
influenza
viru
pandem
increas
knowledg
influenza
infect
confirm
sever
infect
popul
differ
studi
sot
recipi
report
rate
mortal
associ
influenza
infect
rang
sever
case
complic
case
annual
vaccin
season
influenza
effect
strategi
reduc
incid
complic
influenza
infect
shown
reduc
mortal
decreas
risk
graft
loss
transplant
popul
observ
retrospect
studi
adult
transplant
vaccin
within
first
year
transplant
howev
respons
influenza
vaccin
transplant
set
discord
lower
efficaci
gener
popul
seroprotect
rate
vari
suboptim
vaccin
respons
may
partli
result
incomplet
protect
influenza
report
vaccin
highrisk
individu
older
individu
appear
particular
risk
vaccin
failur
perhap
result
immun
senesc
clinic
failur
influenza
vaccin
sot
recipi
extens
studi
retrospect
cohort
studi
evalu
clinic
effect
pandem
influenza
vaccin
patient
show
seroprotect
multicentr
studi
mention
previous
demonstr
rate
clinic
failur
receiv
one
dose
pandem
vaccin
howev
clinic
studi
evalu
impact
anteced
influenza
vaccin
sot
recipi
influenza
diseas
henc
goal
present
studi
evalu
frequenc
nonadjuv
season
influenza
vaccin
among
sot
recipi
influenza
diseas
repercuss
ill
sever
prospect
cohort
observ
studi
conduct
eight
teach
hospit
belong
spanish
network
research
infecti
diseas
reipi
sot
recipi
older
year
diagnos
confirm
influenza
viru
infect
attend
hospit
decemb
april
includ
case
detect
daili
basi
review
microbiolog
report
confirm
case
defin
presenc
influenzalik
ill
laboratoryconfirm
influenza
infect
studi
approv
local
ethic
committe
inform
consent
obtain
subject
studi
carri
consid
current
legisl
ethic
regul
helsinki
declar
guidelin
good
clinic
laboratori
practic
patient
advis
seek
care
hospit
case
respiratori
symptom
one
investig
particip
hospit
evalu
follow
patient
influenza
diagnosi
clinic
data
record
standard
computerassist
protocol
data
collect
demograph
characterist
comorbid
bodi
mass
index
type
transplant
immunosuppress
therapi
time
sinc
transplant
previou
histori
vaccin
clinic
sign
symptom
biochem
analysi
chest
xray
find
antivir
antibacteri
therapi
concomit
secondari
bacteri
infect
time
clinic
stabil
outcom
includ
mortal
followup
visit
took
place
day
diagnosi
complet
protocol
revis
senior
investig
final
valid
case
influenza
infect
diagnos
rtpcr
inf
detect
roch
mannheim
germani
influenza
b
viru
detect
use
detect
set
lightcycl
system
roch
detail
see
supplementari
materi
data
respiratori
viral
infect
test
multiplexpcr
mpcr
detect
kit
seegen
inc
seoul
korea
detect
respiratori
virus
human
metapneumoviru
adenoviru
coronaviru
parainfluenza
rhinoviru
abc
respiratori
syncyti
ab
influenza
ab
enteroviru
bocaviru
concomit
secondari
nonvir
infect
coinfect
consid
bacterium
fungu
isol
least
one
follow
sampl
blood
pleural
fluid
sputum
cultur
bronchial
aspir
bronchoalveolar
lavag
protect
specimen
brush
transbronchi
biopsi
case
posit
urinari
antigen
test
streptococcu
pneumonia
legionella
pneumophila
serogroup
hypogammaglobulinaemia
defin
igg
level
mgdl
pneumonia
defin
presenc
clinic
symptom
fever
dyspnoea
cough
expector
new
pulmonari
infiltr
chest
xray
noninfecti
caus
exclud
sever
diseas
defin
requir
admiss
intens
care
respiratori
insuffici
septic
shock
sever
sepsi
mortal
influenza
ill
allograft
reject
earli
antivir
therapi
defin
administr
antivir
agent
activ
influenza
b
within
h
onset
symptom
recipi
sot
receiv
influenza
season
vaccin
healthcar
centr
part
nation
vaccin
recommend
patient
consid
vaccin
influenza
virus
vaccin
administ
least
week
influenza
infect
antibodi
titr
influenza
strain
determin
use
microneutr
assay
previous
describ
detail
see
supplementari
materi
data
result
analys
use
statist
softwar
packag
spss
version
spss
inc
chicago
il
descript
statist
analysi
perform
proport
calcul
percentag
patient
avail
data
median
interquartil
rang
iqr
continu
variabl
identifi
clinic
manifest
risk
factor
sever
diseas
sot
recipi
influenza
infect
measur
primari
effect
influenza
vaccin
reduc
pneumonia
sever
diseas
incid
compar
proport
vaccin
unvaccin
patient
followup
cohort
calcul
rel
risk
detect
signific
differ
group
use
chisquar
test
fisher
exact
test
categor
variabl
test
mannwhitney
u
test
wilcoxon
test
continu
variabl
appropri
multivari
analysi
logist
regress
use
factor
influenc
risk
pneumonia
rel
risk
rr
ci
geometr
mean
titr
gmt
calcul
take
expon
natur
logarithm
mean
ci
statist
signific
establish
report
p
valu
twotail
total
sot
recipi
includ
patient
requir
hospit
admiss
type
transplant
kidney
liver
heart
four
lung
median
time
transplant
median
time
symptom
onset
influenza
diagnosi
day
iqr
common
manifest
cough
fever
tabl
ten
patient
sever
diseas
pneumonia
requir
admiss
intens
care
four
die
respiratori
virus
detect
sampl
bacteri
coinfect
common
patient
sever
diseas
versu
p
rr
ci
pneumonia
two
case
aspergillu
spp
one
case
patient
sever
diseas
versu
pneumonia
one
case
pseudomona
aeruginosa
two
case
aspergillu
spp
rhizopu
spp
one
case
patient
nonsever
diseas
factor
associ
sever
diseas
chronic
heart
diseas
versu
p
rr
ci
chronic
pulmonari
diseas
versu
p
rr
ci
dyspnoea
versu
p
rr
ci
pneumonia
versu
p
tabl
patient
sever
diseas
initi
antivir
therapi
median
day
day
patient
nonsever
diseas
median
day
day
p
two
patient
mild
diseas
receiv
oseltamivir
therapi
favour
outcom
median
time
antivir
therapi
day
day
versu
day
day
p
sever
mild
case
respect
result
show
anteced
season
vaccin
must
preclud
consider
influenza
infect
sot
recipi
respiratori
symptom
epidem
period
henc
half
patient
influenza
ill
receiv
influenza
vaccin
requir
hospit
admiss
sever
diseas
occur
howev
influenza
vaccin
associ
lower
incid
pneumonia
shorter
length
hospit
stay
sinc
last
pandem
demonstr
influenza
infect
sot
recipi
associ
higher
mortal
rate
gener
popul
mortal
influenza
infect
cohort
associ
bacteri
coinfect
moment
initi
antivir
treatment
prognost
factor
previous
describ
presenc
comorbid
chronic
diseas
time
initi
oseltamivir
treatment
develop
dyspnoea
pneumonia
among
other
administr
annual
influenza
vaccin
current
effect
prevent
strategi
influenza
infect
sot
recipi
although
studi
shown
similar
respons
gener
popul
renal
liver
transplant
recipi
studi
clearli
suggest
reduc
immun
respons
kidney
liver
heart
recipi
howev
knowledg
first
studi
analys
clinic
failur
influenza
vaccin
cohort
sot
recipi
influenza
ill
role
vaccin
clinic
manifest
influenza
infect
popul
present
studi
demonstr
high
rate
season
influenza
vaccin
among
sot
recipi
influenza
especi
relev
influenza
infect
must
rule
influenzavaccin
sot
recipi
respiratori
symptom
pneumonia
pandem
epidem
period
high
index
suspicion
earli
diagnosi
mandatori
given
fact
previous
report
found
time
onset
symptom
initi
oseltamivir
therapi
associ
sever
ill
find
agreement
previou
studi
character
immunolog
respons
influenza
vaccin
sot
recipi
although
studi
shown
similar
respons
renal
liver
transplant
recipi
compar
gener
popul
show
reduc
humor
immun
respons
renal
liver
lung
cardiac
transplant
recipi
seroprotect
rate
vari
lower
seroprotect
rate
vaccin
compar
healthi
subject
howev
result
suggest
receiv
influenza
vaccin
confer
protect
develop
pneumonia
patient
influenza
infect
associ
decreas
risk
develop
pneumonia
shorter
hospit
stay
attenu
diseas
sever
describ
vaccin
polysaccharid
vaccin
pneumonia
test
elderli
vaccin
associ
reduct
risk
death
due
pneumonia
complic
limit
data
similar
effect
avail
nonrepl
influenza
vaccin
studi
perform
transplant
recipi
reduct
ill
sever
even
among
protect
infect
would
enhanc
popul
health
benefit
vaccin
present
studi
nearli
half
patient
receiv
influenza
vaccin
vaccin
indic
beyond
second
month
transplant
protocol
particip
centr
percentag
repres
proport
patient
receiv
vaccin
sot
recipi
popul
nevertheless
effort
made
increas
number
patient
rel
receiv
influenza
vaccin
none
patient
antibodi
titr
respons
vaccin
onset
ill
less
half
seroconvert
week
influenza
diagnosi
howev
patient
develop
sever
symptom
influenza
infect
present
higher
antibodi
titr
convalesc
probabl
result
exposur
increas
influenza
viral
load
trigger
stronger
immun
respons
studi
sever
limit
first
number
patient
includ
studi
may
underpow
demonstr
associ
mortal
rate
previou
vaccin
addit
although
patient
advis
seek
care
hospit
respiratori
tract
infect
symptom
possibl
patient
mild
influenza
infect
attend
hospit
howev
sever
case
influenza
includ
studi
object
studi
evalu
clinic
efficaci
vaccin
determin
vaccin
frequenc
among
clinic
case
influenza
loss
mild
case
invalid
result
show
vaccin
fail
half
sot
recipi
sever
influenza
final
given
associ
sever
seroconvers
episod
respiratori
ill
could
caus
microorgan
detect
influenza
viru
might
relat
asymptomat
colon
howev
although
investig
viral
coinfect
detect
patient
posit
predict
valu
respiratori
symptom
influenza
epidem
period
high
therefor
think
episod
correspond
true
influenza
infect
conclus
respons
sot
recipi
influenza
vaccin
optim
high
rate
failur
among
hospitaltr
influenza
case
demonstr
new
strategi
improv
influenza
immun
need
patient
subgroup
howev
influenza
vaccin
may
confer
protect
develop
influenza
pneumonia
studi
warrant
valid
find
larger
cohort
evalu
impact
outcom
endpoint
mortal
paramet
compar
statist
logist
regress
p
consid
significantli
differ
